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Abstract: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. It includes different
subtypes that differ in their clinical and prognostic features. In the past decade, in addition to the
conventional adenoma-carcinoma model, an alternative multistep mechanism of carcinogenesis,
namely the “serrated pathway”, has been described. Approximately, 15 to 30% of all CRCs arise
from neoplastic serrated polyps, a heterogeneous group of lesions that are histologically classified
into three morphologic categories: hyperplastic polyps, sessile serrated adenomas/polyps, and the
traditional serrated adenomas/polyps. Serrated polyps are characterized by genetic (BRAF or KRAS
mutations) and epigenetic (CpG island methylator phenotype (CIMP)) alterations that cooperate to
initiate and drive malignant transformation from normal colon mucosa to polyps, and then to CRC.
The high heterogeneity of the serrated lesions renders their diagnostic and pathological interpretation
difficult. Hence, novel genetic and epigenetic biomarkers are required for better classification and
management of CRCs. To date, several molecular alterations have been associated with the serrated
polyp-CRC sequence. In addition, the gut microbiota is emerging as a contributor to/modulator of
the serrated pathway. This review summarizes the state of the art of the genetic, epigenetic and
microbiota signatures associated with serrated CRCs, together with their clinical implications.
Keywords: colorectal cancer; serrated pathway; serrated lesions; serrated polyp; CIMP; DNA
methylation; MSI; CIN; serrated adenocarcinoma; gut microbiota
1. Introduction
The Conventional Model of Colorectal Carcinogenesis and the “Serrated” Pathway
Colorectal cancer is a multifactorial and heterogeneous disease [1]. Most CRCs (75%) are sporadic,
whereas about 20% of CRC patients report a family history of the disease. Finally, 3–5% of CRCs
are hereditary, with subjects bearing highly penetrant germline mutations that are associated with
well-defined cancer-predisposing syndromes such as the hereditary nonpolyposis colorectal cancer
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(HNPCC), best known as Lynch syndrome (1–3%), or the familial adenomatous polyposis (FAP) (<1%),
or again the hamartomatous polyposis syndrome, which displays the lowest incidence (<0.1%) [2].
CRC pathogenesis is due to the progressive accumulation of genetic and epigenetic alterations,
some of which being responsible for activating oncogenes or inactivating oncosuppressor genes,
that are able to drive the malignant evolution from normal epithelium through early neoplastic lesions
(aberrant crypt foci, adenomas, and serrated adenomas) to CRC [3,4]. Such malignant transformation
requires up to 15 years, depending on the characteristics of the lesion and on other independent risk
factors such as gender, body weight, body mass index, physical inactivity [5].
Neoplastic transformation affecting the colon epithelium is characterized by two distinct
morphological pathways of carcinogenesis, namely the conventional and the alternative/serrated
neoplasia pathways, each one being defined by specific genetic and epigenetic alterations, typical
clinical and histological features and leading to different phenotypes [6–8].
The conventional model, the so-called adenoma-carcinoma sequence, is histologically homogeneous
and morphologically characterized the adenoma, including tubular or tubulovillous adenoma, as a
precursor lesion [1]. The adenoma-carcinoma sequence is a multistep mutational pathway, in which
each histological alteration is the consequence of a molecular dysregulation [9–12]. At the molecular
level, this model recognizes a heterogeneous background, based on two mechanisms of tumorigenesis:
(i) chromosomal instability (CIN) or (ii) microsatellite instability (MSI) [13–16] (Figure 1).
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Figure 1. Conve tio al adenoma-to-carcinoma sequence. The chromos al instability (CIN) pathway
begins ith bi-allelic mutations in the tumor suppressor gene APC withi the normal colonic mucosa.
The latter progressively differentiate into adenocarcinoma upon acquisition of additional mutations in
the genes KRAS, SMAD4, and TP53, with consequent dysregulation of the Wnt/β-catenin, MAPK, PI3K
and TGF-β signaling pathways. Alternatively, the MSI pathway involves an initial alteration of the Wnt
signaling that leads to the formation of an early adenoma. Then, BRAF mutation followed by alterations
of the genes TGFBR2, IGF2R, and BAX, participate in the progression toward the intermediate and late
stages of carcinogenesis.
CIN represents the most prevalent form of genomic instability. It is detected in 85% of sporadic
CRCs and is frequently observed in distal, rather than proximal, colon cancer sites [15,16]. CIN
consists of a gain or loss of all or part of chromosome(s), and is usually associated with mutations in
proto-oncogenes or tumor suppressor genes, such as KRAS or APC, respectively [13,16].
MSI occurs in about 15% of CRCs, predicts a favorable outcome in CRC and can also be detected
in the serrated pathway [15,17–19]. This genomic instability does not affect chromosomal integrity but
consists of an accumulation of insertions/deletions of short nucleotide repeats (microsatellites) that
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is consecutive to hereditary (5%) or sporadic (10%) alterations in genes involved in DNA mismatch
repair (MMR) [14,15].
Although MSI, according to the National Cancer Institute, is frequently determined using a panel
of five markers (BAT25, BAT26, D2S123, D5346, and D17S250), a variety of commercially available
panels are currently used in most laboratories [20]. Depending on the number of microsatellites
associated with these markers, tumors have been subclassified into: (i) high, labeled “MSI”, (ii) low,
labeled “MSI-L” or (iii) stable, labeled “MSS” [21]. MSI-L tumors have been regrouped with MSS
tumors, due to low differences in their clinicopathological characteristics or in most of their molecular
features [22].
Approximately, 3–15% of all CRCs are represented by sporadic forms with MSI [21,23]. Several
studies have demonstrated that epigenetic hypermethylation (80% of MSI CRCs), and the consequent
silencing and inactivation of the gene MLH1, is the event that triggers malignant transformation and
determines a high rate of MSI [21,23]. Moreover, mutations in MMR genes (20% of MSI CRCs) can
also determine MSI tumors, associated with HNPCC (3% of CRCs) [21,23]. HNPCC is an autosomal
dominant disease due to germline mutations in some MMR genes (e.g., MSH2, MLH1, MSH6, PMS2,
and PMS1), causing consequent inactivation of the DNA repair system and the accumulation of
mutated microsatellites [24]. In addition, germline deletions in the 3’ end of EPCAM result in epigenetic
inactivation of the adjacent gene MSH2 and represent another mutational mechanism responsible for
HNPCC (1–3% of HNPCC patients) [25]. HNPCC is not characterized by MLH1 hypermethylation.
Thus, MSI analysis, in addition to MLH1 evaluation and BRAF mutation analysis, is currently one of
the first steps for the diagnosis of this disease [24,26].
In contrast to the conventional adenoma-carcinoma pathway, an alternative pathway, featured
by the presence of serrated adenomas/polyps as precursor lesions, has been documented over the
last 10 years [21,27–31]. It has been estimated that 15 to 30% of all CRCs arise from early neoplastic
serrated lesions. These lesions, that are histologically characterized by a “serrated” (or saw-toothed)
appearance of the epithelial glandular crypts within the precursor polyps, have long been considered
innocuous [31–34]. Nevertheless, serrated lesions are among the main causes of the “interval” CRCs
and are associated with synchronous and metachronous advanced colorectal neoplasia [35,36].
At the molecular level, serrated colorectal lesions rarely present truncating APC mutations.
The majority of CRCs arising from serrated lesions carry BRAF mutations (whose prevalence varies
among the different serrated subtypes), while KRAS mutations remain less frequent. They are also
associated with two pathways, namely MSI and the CpG island methylator phenotype (CIMP), which
are involved in genomic instability; the latter being considered as the major mechanism that drives the
serrated pathway toward CRC [37,38].
Although the role of APC mutations, and the subsequent aberrant activation of the WNT pathway,
is fully understood in the conventional adenoma-carcinoma sequence, its role in the serrated pathway
remains unclear. To address this issue, the mutational landscape of APC in serrated precursors and
BRAF mutant cancers has been recently explored [39]. In the cited study, even if the WNT pathway was
notably activated in dysplastic serrated lesions and BRAF mutant cancers, it was not due to truncating
APC mutations, suggesting the existence of alternative mechanisms of activation of the WNT signaling.
Moreover, the role of missense APC mutations, which are relatively frequent in serrated lesions and
BRAF mutant cancers with MSI, should be further investigated in the serrated pathway.
Overall, CRCs have been classified into five molecular subtypes based on their MSI and CIMP
status, among which the three following signatures describe serrated lesions [21]:
• CIMP-H, MLH1 methylated, MSI, BRAF mutated lesions, known as sporadic MSI;
• CIMP-H, MLH1 partially methylated, MSS, BRAF mutated lesions;
• CIMP-L, MGMT methylated, MSS, KRAS mutated lesions.
However, alternative molecular classifications have been proposed based on recent findings, such
as those defined by the CRC Subtyping Consortium (CRCSC) or by Fennell et al. [40–42].
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The heterogeneity of serrated lesions and the presence of morphological features shared with
different subtypes, make difficult the accurate CRC classification during the diagnostic process and
also the physiopathological interpretation of the observed lesions. In addition, serrated lesions with
a distinctive endoscopic appearance are more difficult to detect compared to conventional lesions.
In fact, detection of serrated lesions, particularly those located in the proximal colon, is difficult and
endoscopist-dependent [43,44]. Therefore, characterization of molecular markers specific for each
CRC subtype may improve the identification of CRCs arising from this alternative pathway, and
consequently support the diagnostic process as well as the clinical decision-making.
This review will focus on the genetic and epigenetic features involved in the development of
the serrated lesion patterns and their relationship with CRC development. In particular, since the
methylation status has emerged as a relevant biomarker for CRC classification/prognostic evaluation
and is also involved in the progression of serrated lesions toward carcinoma, we will first describe
the methylation alterations related to CRCs. Then, the genetic and epigenetic alterations related to
serrated precursor lesions and to the serrated pathway will be detailed, with particular attention on
one of the endpoints of the serrated pathway, namely the serrated adenocarcinoma.
We will also report the recently discovered superficially serrated adenomas subtype as well as the
association between gut microbiota and the serrated pathway. Finally, the clinical implications of the
serrated colorectal pathway will be discussed.
2. Histopathological and Endoscopic Features of Serrated Colorectal Lesions
Serrated neoplasia of the colorectum represents one of the CRC subtypes [45]. They are
histologically classified by the World Health Organization (WHO) into three morphological categories:
(i) hyperplastic polyp (HP), (ii) sessile serrated adenoma/polyp (SSA/P) with or without cytological
dysplasia (SSAD), and (iii) the traditional serrated adenoma/polyp (TSA) (Figure 2) (Table 1) [46].
The serrated subtypes, identified by their cytological characteristics and lesion area, have a distinct
endoscopic appearance, share some histological features, and are unique at the biological and molecular
levels [34,47].
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Figure 2. Representative endoscopic appearance of serrated lesions of the colorectum. (a) Hyperplastic
polyp; (b) Sessile serrated adenoma/polyp; (c) Sessile serrated adenom /polyp with dysplasia;
(d) Traditional serrated adenoma. (Courtesy of Prof. Dr. Giovanni D. De Palma, University of
Naples Federico II, Naples, Italy).
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Table 1. Morphologic categories and features of serrated colorectal lesions.
Histological Classification Frequency (%) * Location Shape Mucin Type Size
Hyperplastic polyp (HP) 80–90% Distal Sessile, Flat Variable <5 mm
Microvesicular HP (MVHP) 60% Distal Sessile Microvesicular <5 mm
Goblet cell HP (GCHP) 30% Distal Sessile Goblet cells <5 mm
Mucin poor HP (MPHP) 10% Distal Sessile Poor <5 mm
Sessile serrated adenoma/polyp (SSA/P) 15–20% Proximal Sessile/Flat Microvesicular >5 mm
Traditional serrated polyp (TSA) 1–6% Distal Sessile/Pedunculated Not present >5 mm
* Frequency of all serrated polyps.
HP precursor lesions are the most frequent polyps (80–90%) and mostly remain benign (Figure 2a)
(Table 1) [48]. HPs may be flat or sessile, are preferentially located in the distal colon, show a smaller
size (< 5mm) than other subtypes, and remain hardly detectable by endoscopic exam. Based on
the epithelial mucin content, HP lesions can be histologically subclassified into microvesicular HP
(MVHP), goblet cell HP (GCHP), and mucin poor HP (MPHP) polyps (Table 1) [28,30,34]. Although
the frequency of each HP subtypes is variable, MVHPs are the most common, while MPHPs are the
rarest form of HPs [49,50].
SSA/Ps, which account for 15 to 20% of all serrated polyps, especially develop in the proximal
colon, are pale lesions that can be either sessile or flat, with a variable size usually larger than 5 mm
in diameter (Figure 2b) (Table 1) [48,51,52]. SSA/Ps can develop either as primary tumors or evolve
from hyperplastic polyps. SSA/Ps lesions cannot be easily distinguished from MVHPs, however,
MVHPs larger than 10 mm in diameter can be considered clinically equivalent to SSA/Ps. Additionally,
SSA/Ps can be subclassified according to the absence or presence of dysplasia (SSAD); the latter being
detected in about 0.20% of all serrated lesions (Figure 2c) [51]. Overall, by combining both serrated and
dysplastic features, SSADs consist of advanced lesions that usually evolve rapidly toward carcinoma.
TSA lesions are the rarest form of colorectal serrated polyps (1–6%) (Figure 2d) (Table 1) [34,48].
TSAs, that arise either from HPs or SSA/Ps, are precancerous sessile or, more often, pedunculated
polypoid lesions, which preferentially develop in the distal colon and rectum, and show a larger size
(>5 mm) than HPs [50]. A less aggressive variant form of TSA is the filiform serrated adenoma [53]. TSA
can also be subclassified according to the presence of dysplasia that can be of two types: the well-known
“adenomatous dysplasia” and the less frequently observed “serrated dysplasia”, which is related to the
serrated pathway. The latter can be graded as low- or high-grade dysplasia depending on the absence
or presence of cytological and architectural atypia, respectively. Recently, it has also been evidenced
that TSA can co-exist with other lesions such as HPs, SSA/Ps and tubulovillous adenomas [54]. Usually,
only TSA with serrated dysplasia develops into invasive carcinomas.
3. CpG island Methylator Phenotype, an Epigenetic Signature of Serrated Colorectal Lesions
Methylation is one of the epigenetic mechanisms that regulate gene expression [55,56]. Precisely,
it consists of biochemical modification of the DNA that is catalyzed by DNA methyltransferases and
results in the covalent addition of a methyl group (CH3) to the carbon 5 of the cytosine ring of CpG
islands (Cytosine-Guanine dinucleotide group) located in gene promoter regions [56].
DNA methylation (mDNA) is a regulatory mechanism used by cells to silence the expression of a
target gene, such as a tumor suppressor gene. In particular, when a CpG site is methylated within
the promoter region of a gene, its transcription is inhibited. Aberrant DNA hyper/down-methylation
is involved in several diseases, including cancer [57]. Interestingly, assessing the methylation status
of specific genes could be useful in clinical practice. Indeed, it could represent a biomarker for the
detection or monitoring of specific diseases such as CRC, and more particularly of the serrated lesions
that are associated with a CIMP signature [58–60]. For instance, a recent study reported on a positive
correlation between CIMP and older age in SSA/Ps, indicating a lower risk of developing a malignancy
in young patients [61].
It has been estimated that 20–30% of all CRCs harbor the CIMP phenotype [62–64]. In serrated
lesions, although the CpG island methylation can occur in crypt foci and small HPs, the normal
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mucosa of patients affected by hyperplastic polyposis (HPP) or CRC has demonstrated promoter
hypermethylation in some specific genes, accompanied with genetic predisposition to such epigenetic
event [22,65,66].
CIMP represents a distinct phenotype in CRC, with specific clinical, pathological and molecular
features [64,67]. The origin of CIMP, including its association with BRAF mutation remains controversial.
Several hypotheses, such as the implication of BRAF or MAFG, have been explored [68,69]. Using
a mouse model of colon derived-organoids, Tao et al. have recently demonstrated that aging-like
spontaneous methylation of multiple genes produces a cell that avoid BRAF-induced senescence, and
predisposes colon cells to oncogene-driven carcinogenesis [70].
CIMP can be graded as low (CIMP-L), high (CIMP-H) or negative (CIMP-0), depending on the
degree of simultaneous hypermethylations occurring in several CpG islands located near the promoter
region of tumor suppressor genes (Table 2) [71,72].
Table 2. Characteristics of CpG island methylator phenotype (CIMP) subtypes bearing serrated
colorectal lesions.
CIMP Phenotype CIMP-0 CIMP-L CIMP-H
Location Distal colon Proximal colon Proximal colon
Gender no gender bias Male Female
Pathway Conventional adenoma Serrated or Conventional Serrated adenoma
Gene mutations TP53 mutations KRAS, TP53 mutations BRAF mutations
Epigenetic alterations no MLH1 methylation no MLH1 methylation MLH1 hypermethylation
MSI rate MSS MSS MSI
CIN association positive positive negative
Prognosis Variable High Poor
CIMP-H, which is preferentially localized in the proximal colon, occurs more frequently in females
and in older age, and shows the poorest prognosis compared to CIMP-L [62,73]. At the molecular level,
CIMP-H is often a MSI tumor and is featured by the inactivation of WNT/β-catenin pathway, high
BRAF and low TP53 mutation rates. In comparison, CIMP-L is associated with KRAS mutations while
CIMP-0 is characterized by frequent mutations in TP53 (Table 2) [62,74].
Although the categorization and the cut-off between the CIMP high and low phenotypes have
been modified several times over the last years, there are currently two panels of genes used to define
the CIMP phenotype. The first one was described by Toyota and considers p16, hMLH1, MINT1, MINT2,
and MINT31, while the second panel has been described by Weisenberger and takes into consideration
CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1. These panels allow to verify the transcriptional
inactivation of the genes mentioned and involved in the carcinogenetic development [75,76].
As described above, the hypermethylation status of the genes listed in the CIMP panels can
be used as a biomarker for prognosis, prediction, diagnosis and response to chemotherapy of CRC.
For instance, evaluation of the methylation status of the MLH1 promoter is nowadays added to genetic
testing for the hereditary Lynch syndrome, usually MLH1 negative [24].
Another epigenetic marker is O(6)-methylguanine-DNA methyltransferase (MGMT) [21,77].
Hypermethylation of the MGMT promoter is preferentially associated with KRAS mutations, CIMP-L,
MSS phenotype due to the overloading of the DNA mismatch repair system. The methylation and
the loss of MGMT are highly variable among the CRC subtypes, occurring usually in 22% of HPs,
25% SSA/Ps, 16–22% serrated adenoma, and 50% of serrated adenocarcinoma, but is less frequently
associated with HNPCC (6%) [77].
Different methylome-based studies, as the recent one of Parker et al., have identified candidate
markers for DNA methylation in serrated CRC, notably for the pre-colonoscopy detection of
precancerous lesions [78]. These biomarkers of precancerous serrated lesions include BMP3, NDRG4,
ANXA10 and are analyzed through stool DNA tests. They allow distinguishing between SSA/Ps and
conventional adenomas [79,80].
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Genome-scale mDNA studies have also been applied to better characterize the DNA methylation
subtypes in CRC. In light of the identification of four DNA methylation–based subgroups of CRC, five
clinically and molecularly distinct CIMP subtypes in CRC (CIMP-H1, CIMP-H2, CIMP-L1, CIMP-L2
and CIMP-neg), based on a comprehensive methylome-based study and validated in a larger cohort
of CRC data from TCGA, have also been identified recently [42,81]. In this new scenario, the major
difference between this latter and the current CIMP classification is the dichotomization between
CIMP-H1 and -H2 cancers. While CIMP-H1s are characterized by female gender preponderance, and
proximal colon location for BRAF mutated tumors, CIMP-H2s are preferentially located in distal colon
and frequently harbor KRAS mutations.
At present, there are several gene methylation analysis methods to define the CIMP-CRC profile,
such as the non-quantitative methylation-specific PCR (MSP) technique or the high-throughput
quantitative methylation PCR MethyLight assay. In addition, pyrosequencing, InfiniumMethylation
bead array, MassARRAY, methylation-sensitive high-resolution melting (MS-HRM), next generation
sequencing (Methyl-Seq) and combined bisulfite restriction analysis (COBRA) methods can also
be used.
Although the comprehension of the epigenome landscape needs to be extended, the identification
of specific epigenetic alterations driving tumor progression has become crucial to better classify the
heterogeneous molecular subtypes of CRC. Ultimately, it will facilitate the development of innovative
epigenome-based personalized medicine strategies.
4. Molecular Features of the Serrated Colorectal Precursor Lesions
4.1. Hyperplastic Polyps
As described above, hyperplastic polyps can be histologically subclassified into MPHP, GCHP
and MVHP lesions (Table 1). The endoscopic diagnosis between these subtypes, and furthermore
between HPs and SSA/Ps, is difficult and may be supported by the detection of specific biomarkers.
MPHP is the rarest form of HP and is not well described; in fact, to date, it has only been associated
with CIMP-H (Table 3). MVHP and GCHP are the most common HP subtypes. At the molecular level,
MVHP is particularly characterized by BRAF V600E mutation and CIMP-H (Table 3); for that reason,
it is considered a precursor of SSA/Ps [17,82].
Table 3. Molecular profile of serrated colorectal lesions.
Serrated Lesion BRAF/KRAS Status CIMP Rate Gene Methylation MSI Rate
HP BRAF mutated CIMP-H MLH1 not methylated MSS
MPHP * controversial CIMP-H controversial controversial
GCHP * KRAS mutated CIMP-L MLH1 not methylated MSS
MVHP * BRAF mutated CIMP-H MLH1 not methylated MSS
SSA/P BRAF mutated CIMP-H MLH1 not methylated MSS
SSAD BRAF mutated CIMP-H MLH1 hypermethylated MSI
TSA KRAS/BRAF mutated or neither CIMP-L/-H MLH1 not methylated MSS
TSA HGD KRAS mutated CIMP-L MGMT hypermethylated MSS
* MPHP, GCHP, MVHP are HP subtypes.
GCHP is linked to KRAS mutations (often missense substitutions at glycine codons 12 or 13)
and CIMP-L (Table 3) [19,83]. Mutations in BRAF or KRAS, that rarely coexist in CRC, constitutively
activate the MAPK signaling pathway, which is involved in the regulation of several cellular processes,
and inhibit the apoptosis mechanism, thus supporting tumor cell proliferation.
To shed light on other molecular features of HP lesions, early markers of potentially malignant
serrated precursor lesions have been identified, such as MUC5AC [84,85]. MVHP and SSA/P
lesions present an hypomethylated MUC5AC when compared to GCHPs. Interestingly, this gene
hypomethylation occurs early in the serrated pathway, gradually increasing from MVHP to SSA
and SSAD, and is particularly related to lesions with BRAF mutations, CIMP-H and MSI. Thus,
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the epigenetic alteration of MUC5AC could be a potential marker to evaluate the malignant evolution
of serrated precursor polyps.
4.2. Sessile Serrated Adenoma/Polyps
At the molecular level, SSA/Ps are mainly characterized by BRAF mutations, MSS, CIMP-H
and unmethylated MLH1 (Table 3) [17,86]. Other molecular characteristics of sessile serrated lesions,
as well as a subtype-specific gene signature, have been explored and, in some cases, identified based
on epigenetic and transcriptomic approaches. An example is the recent molecular characterization of
SSA/Ps in a large African American cohort, in which the over-expression of FSCN1 and TRNP1 seemed
to segregate with race [87].
The formation of SSA/Ps has been associated with the tumor suppressor gene SLIT2, who is
down-expressed in SSA/Ps compared to TSAs/adenomas/normal tissues as a result of promoter
hypermethylation and loss of heterozygosity [88]. The high rate of SFRP4 methylation in SSA/P
compared to the corresponding adenoma series has also been evidenced [86]. CTSE, TFF1 and ANXA10
were identified as potential clinical markers of SSA/P lesions [89–91]. In particular, ANXA10 expression
levels significantly increased at the gene and protein levels in SSA/Ps in comparison to MVHPs [90,92].
Hes-1, a downstream target of the Notch signaling pathway which involved in intestinal development,
has also been described as a SSA/P-specific biomarker due to its immunohistochemical (IHC) loss of
expression in SSA/Ps compared to HPs or normal colonic mucosa [93].
In a large-scale study, differentially expressed genes and immunohistochemical markers were
also identified when comparing SSA/Ps to controls [94]. In particular, among the 1294 genes
identified, VSIG1 and MUC17, were uniquely and significantly increased in SSA/Ps with respect
to controls/HPs/adenomas, thus evidencing a molecular signature specific of the polyps and the
involvement of different molecular pathways across distinct CRC lesions.
Recently, a platform-independent approach was adopted in order to differentiate SSA/P from HP
lesions [95]. SSA/Ps have been characterized by a specific molecular profile of up-/down-regulated
genes involved in the inflammatory process, immune response, epithelial–mesenchymal transition
(EMT), extracellular matrix (ECM) interaction, cell migration and cell growth. This profile defines the
malignant potential of SSA/P lesions and allow to distinguish them from HPs.
As for MVHP polyps, SSA/P immunohistochemically expresses MUC2, MUC5AC and
MUC6 [84,96]. The role of MUC6 was evaluated in SSA/Ps lesions and is controversial [84]. Nevertheless,
MUC6 was assessed to be a supportive immunohistochemical marker to differentiate SSA/Ps from
TSAs [97,98].
4.3. Sessile Serrated Adenoma/Polyps with Dysplasia
The main molecular characteristics found in SSADs are BRAF mutations, a nuclear β-catenin
accumulation, CIMP-H and MSI as a consequence of MLH1 gene silencing due to promoter
hypermethylation (Table 3) [99]. Although the loss of MLH1 expression is related to the development
of dysplasia, MLH1 inactivation can also be detected in SSA/P non-dysplastic crypts, indicating the
putative biomarker role of MLH1 in predicting dysplastic progression of these polyps [100].
Moreover, it has been demonstrated that SSAD lesions can be also associated with MSI, harboring
different genetic alterations [99]. In particular, MSI lesions are characterized by a high mutational
rate of FBXW7 and the loss of MLH1 expression, while MSSs display TP53 mutations without FBXW7
mutations. Thus, FBXW7 alterations can be correlated to the progression of MSI serrated lesions
in CRC.
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SSAD polyps, and particularly the progression of SSA/P lesions toward dysplasia, can also be
characterized by alterations in WNT signaling-associated genes like protein-truncating mutations
of RNF43, APC, ZNRF3 and the hypermethylation of AXIN2 and MCC [99,101–103]. Furthermore,
frameshift mutations in RNF43 are frequently present in patients with MLH1-deficient SSA/P with
dysplasia [101].
Genetic variants of DNA-regulatory elements, such as single nucleotide polymorphisms (SNPs),
can influence gene expression and be associated with cancer risk. An example is the well-known
CRC-associated rs1800734, or MLH1-93G>A, which can be detected in the promoter region of MLH1.
This SNP enhances DCLK3 expression which in turn promotes CRC development [104]. MLH1–93
G/a polymorphism has been significantly associated with MLH1 hypermethylation in SSAD lesions
compared to TSAs, and represents a putative risk factor for MLH1 promoter methylation [105].
4.4. Traditional Serrated Adenoma/Polyps with and without Dysplasia
TSA is an enigmatic subtype due to its heterogeneous molecular features [54,106]. TSAs can
harbor KRAS or BRAF mutations, or neither, and can be CIMP-low or high, and MSS (Table 3) [107].
In contrast with SSA/Ps, TSA lesions do not show MLH1 promoter hypermethylation but can present
MGMT hypermethylation (Table 3) [108]. Evaluation of the mutational status of WNT genes in TSA
lesions has identified precursor- and TSA-specific alterations that elucidate the mechanism involved in
the genetic transition from precursor polyps to TSAs [109]. PTPRK-RSPO3 fusion and mutations in
PTEN, RNF43, APC, or CTNNB1 are genetic features of TSAs [110,111].
Several epigenetic biomarkers have also been associated with TSA. An example is SMOC1 which
is down-expressed, due to methylations in its promoter region, in TSAs as compared to SSA/Ps [112].
In particular, SMOC1 methylation increases during TSA development and has been correlated with
KRAS mutation and CIMP-L. In addition, low expression of the SMOC1 protein in TSA can be verified
by IHC assay, supporting its exploitation as a TSA-specific diagnostic biomarker.
The transition of TSAs toward dysplasia is characterized by nuclear β-catenin accumulation,
TP53 mutation and p16 inactivation, as detailed below [21]. TSA-HGDs are usually characterized by
CIMP-H, BRAF mutations and MSS (Table 3). The high rate of differentially methylated region in the
promoter P0 of IGF2 gene (IGF2 DMR0) and hypomethylation of LINE-1 are two epigenetic biomarkers
of TSA-HGD [113]. LINE-1 hypomethylation in CRC has been associated with early age onset and
family history of CRC. In several studies, LINE-1 hypomethylation has been inversely correlated with
MSI and CIMP-H phenotypes. Interestingly, the methylation level of LINE-1 has recently been assessed
from plasma-circulating cell-free DNA, thus comforting a putative role as a preventive biomarker in
CRC [114,115].
5. Serrated Adenoma to Carcinoma Sequence: Initiation and Progression
The colorectal carcinogenetic mechanisms that drive malignant transformation from the normal
colon mucosa to serrated polyp, then to carcinoma can be distinguished in traditional and sessile
serrated pathways based on the lesions involved in the oncogenic process, TSA and SSA/P respectively,
and on different molecular features: BRAF or KRAS mutations, hypermethylation of CpG islands and
MSI status (Figure 3) (Table 3) [29,33].
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Figure 3. Representation of the two serrated pathways. The sequence leading to serrated Colorectal
cancer (CRC) can occur in two different molecular pathways, the sessile and the traditional serrated
routes. The tumorigenic process involves progressive accumulation of specific genetic and epigenetic
hits affecting normal colon epithelial cells. In the sessile serrated pathway, the transformation of the
normal mucosa begins with BRAF mutations, followed by p16 and IGFBP7 promoter hypermethylation
and the consequent progression toward serrated adenocarcinoma, mainly through MLH1 epigenetic
alterations. In contrast, the traditional serrated pathway involves KRAS or BRAF mutations in normal
colon cells which, together with MGMT or other gene methylation alterations, malignantly evolve
toward traditional serrated adenoma (TSA) high-grade dysplasia and serrated adenocarcinoma (SAC).
Cancers arising through the traditional serrated pathway are predominantly localized in the distal
colon and rectum. This pathway is the most controversial due to the molecular heterogeneity of the
TSA lesions. The carcinogenetic mechanism that drives malignant transformation is KRAS or BRAF
mutation in normal colon which consequently evolves toward a TSA lesion [29]. This pathway is
characterized by a CIMP phenotype and is rarely associated with MLH1 hypermethylation (Table 3).
TSAs can progress toward dysplasia via two different molecular pathways [116]. Usually, TSA
lesions which harbor KRAS mutations evolve toward conventional adenomatous dysplasia, while
TSAs, which display BRAF mutations progress toward serrated dysplasia. Moreover, both dysplastic
lesions can advance toward HGD due to aberrant promoter methylation of some genes. Among these
latter, MGMT is usually associated with CIMP-L and MSS status (Figure 3). Finally, progression toward
invasive carcinoma is driven by TP53 alterations [116].
The sessile serrated sequence begins in the proximal colon with a BRAF activating mutation
that alters the MAPK-ERK pathway, inducing apoptosis arrest, colonocyte proliferation and p16 and
IGFBP7 over-expression (Figure 3) [30]. These changes determine the transformation of the normal
mucosa into hyperplastic crypts, which then, due to p16 and IGFBP7 promoter hypermethylation,
evolve toward sessile serrated adenoma. In particular, HP lesions can stay dormant for a long
time due to oncogene-induced senescence which inhibits the tumorigenic progress until an aberrant
methylation of the p16 and IGFBP7 promoters subverts this protective mechanism. P16 and IGFBP7
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are tumor suppressor genes: IGFBP7 is a direct target and mediator of p53-dependent growth
suppression, while p16 encodes for the p16 protein that negatively regulates the p16/cyclin-dependent
kinase/retinoblastoma gene pathway involved in the control of the cell cycle [117,118].
The oncogene-induced senescence process in CRC was first investigated in mice [119]. Then,
the same mechanism has also been evidenced in human serrated polyps [118].
In human CRC, p16 methylation is usually linked to CIMP-H and MSI phenotype, and is
particularly associated with SSA/Ps with respect to HP and TSA tumors. In fact, in addition to the
BRAF-mediated alteration of the MAPK pathway, the inactivating hypermethylation of p16 and IGFBP7
drives the progression of MVHP lesions toward sessile serrated adenomas/polyps, rendering the
distinction between MVHP and SSA/P difficult to assess by endoscopy. Nevertheless, their distinction
is clinically relevant due to their disparate outcome and relative interval of surveillance.
The next stage of polyp progression is the evolution of SSA/P lesion toward sessile serrated
adenoma with high-grade dysplasia. This malignant evolution can be related either to MLH1 aberrant
methylation with consequent amplification of microsatellites (MSI), usually representative of a good
prognosis, or to MGMT hypermethylation with a stable number of microsatellite (MSS), associated
with the poorest prognosis (Figure 3) (Table 3) [29,31].
The serrated pathway has two end results that differ in their clinical and prognostic features as
well as in their methylome profile: (i) the serrated adenocarcinoma (SAC) or (ii) the sporadic colorectal
carcinoma showing histological and molecular features of MSI-H (hmMSI-H) [31,120]. The CRC
subtype hmMSI-H is associated with a dense immune infiltrate and shows a better prognosis than
SACs [120].
A Distinct Variant of Colorectal Cancer: Serrated Adenocarcinoma
Serrated adenocarcinoma (SAC), which was first described by Jass and Smith in 1992, is histologically
defined as an adenocarcinoma with serrated architecture and is one of the endpoints of the serrated
pathway [121,122]. SAC accounts for 7.5–8.7% of all CRCs. It is located predominantly in the cecum
and rectum, occurs particularly in females and has a worse prognosis than conventional carcinoma
(CC) [121,123]. At the molecular level, SAC is a heterogeneous subtype. KRAS mutations, particularly
the c12 G>A substitution, but predominantly BRAF alterations, are frequent [124]. Although SACs
mainly arise from TSA lesions and show a MSS phenotype, about 20% of them originate from SSA/Ps
and are MSI.
Several studies have indicated PTCH1, HIF1α and EPHB2 as SAC biomarkers [121,125–127].
PTCH1 expression is decreased, while HIF1α is increased in SACs in comparison to CC, evidencing
the molecular and histopathological differences between the two classes of CRC [125]. EPHB2, which
encodes a tyrosine kinase receptor, is one of the most studied genes related to SAC [128]. EPHB2
is a well-established tumor suppressor gene whose downregulation often results from promoter
hypermethylation [129]. The decreased expression of EPHB2 in serrated CRC may also potentiate the
activation of the Notch signaling pathway which can further stimulate the expression of EPHB4 [128].
EPHB2 frameshift mutations are also frequent in MSI adenomas and carcinomas. Furthermore, a novel
biomarker of SAC has recently been reported and consists of fascin-1 (FSCN1) whose over-expression
has been associated with a progression from adenoma to carcinoma [127,130].
Methylome profiling has been performed in order to identify some genes that are differentially
methylated between SAC and CC. DIO3 and FOXD2 appeared more methylated and less expressed
at the mRNA level in SAC than in CC, thus revealing a SAC-associated epigenetic signature [131].
Differences in the molecular signature between SAC and hmMSI-H have also been studied. CD14
and HLADOA were the most significantly hypermethylated and underexpressed genes in hmMSI-H
as compared to SAC [120]. In addition, gene expression profiling was carried out in order to clarify
the role of the immune response between the two end results of the serrated pathway. As a result,
a higher expression of ICAM1, an adhesion molecule involved in cellular immune responses, and a
lower expression of CRCP and CXCL14 were identified in SAC versus hmMSI-H CRCs [132].
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Additional studies will be necessary to further characterize SAC at a molecular level, not only to
better clarify the malignant process of CRC progression but also to identify novel biomarkers for SAC
targeted therapy.
6. Superficially Serrated Adenoma
A novel subtype of CRC, namely superficially serrated adenoma, has been recently described [133].
It is characterized by mixed morphological features of both conventional and serrated adenomas.
Superficially serrated adenomas show a median size of 5 mm and are preferentially located in the
sigmoid colon or rectum. They appear like SSA/P polyps. However, in some cases, they can look like
larger and flat lesions. At the molecular level, superficially serrated adenomas are homogeneous. KRAS
mutation, RSPO fusion/overexpression and MLH1 loss are the most frequent alterations. BRAF, APC
and GNAS mutations are present only in a few lesions. IHC analysis also revealed that superficially
serrated adenomas show an overexpression of MYC, a nuclear accumulation of β-catenin and express
Ki-67 preferentially in the upper half of the crypts.
Although identification of this novel type of polyp can contribute to better distinguish CRC
subtypes, further studies will determine if superficially serrated adenoma can be subcategorized [133].
7. MicroRNAs and Long Non-Coding RNAs in Serrated Colorectal Pathway
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two important classes of RNAs
involved in the regulation of gene expression [134]. Their altered expression has been described in CRCs,
with distinct profiles observed between the conventional adenoma-carcinoma and serrated-carcinoma
progression models [135–137]. Even if their role in cancer progression has not been elucidated yet,
specific miRNA alterations have also been described in pre-cancerous lesions.
In this scenario, miR-31 is frequently overexpressed in sessile serrated adenomas suggesting an
involvement in the progression of serrated lesions [138]. Interestingly, several studies showed an
unique miRNA signature in different types of polyps. In this line, HPs and SSPs share a similar profile
of miRNAs characterized by the down-regulation of a set of miRNAs, while normal colonic mucosa
shows an up-regulation of miRNAs [139]. Another miRNA profiling in 109 patient biopsies allowed to
discriminate between five different histopathologic groups [135]. In particular, the expression levels of
miR-335, miR-222, and miR-214 were able to distinguish between non-serrated and serrated histology.
Precisely, miR-335 was significantly overexpressed in non-serrated tissues compared to serrated lesions.
Moreover, miR-222 and miR-214 were significantly downregulated in serrated polyps [135]. Finally,
this study identified miR-125b and miR-320a as predictive biomarkers of the evolution toward CRC
through the serrated pathway [135].
In a recent study, small RNA sequencing has been performed in 108 colon biopsies with different
histology. Differential expression of miRNAs between tumor and healthy mucosal specimens was
highlighted, and miRNAs specific of the serrated lesions were identified [136]. In particular, 23 miRNAs
appeared differentially expressed between the serrated lesions and their paired healthy colon samples.
Also, six miRNAs were differentially expressed between the serrated lesions and the hyperplastic
polyps, with miR-31-5p being the most significantly modulated.
Similar results were observed for lncRNAs. Characterization of the lncRNA expression profiles
in 888 CRC samples identified five different molecular clusters. These latter allowed to distinguish
the conventional pathway from the serrated one [140]. Recently, the expression of 4898 lncRNAs has
been monitored in 566 CRC samples and 282 lncRNAs illustrated the heterogeneity of CRCs [137].
Because the latter lncRNAs seem relevant for the development of CRC, their study may contribute to
better understanding the origin of such tumor heterogeneity and facilitate the development of novel
therapies [137].
Altogether, these findings show that non-coding RNAs may be useful to further discriminate the
different subtypes of CRCs.
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8. Dysbiosis of the Gut Microbiota: A New Biomarker?
About 39 trillion microorganisms colonize the adult gut system, resulting in a biomass of 0.2 kg [141].
Human gut microbiota, whose composition varies across gut segments and between individuals, plays
a multitude of functions, such as structural and metabolic roles or homeostasis maintenance of the
intestinal immune system which constitutes a natural barrier to pathogen infection [142,143].
The plethora of bacterial species found in the human gastrointestinal tract belong to three phyla:
Firmicutes (30–50%) Bacteroidetes (20–40%) and Actinobacteria (1–10%) [144]. Environmental factors
(infection, antibiotics, diet, lifestyle) can trigger an imbalance in the composition of the gut microbiota,
known as dysbiosis. Dysbiosis has been associated with several diseases. In particular, it may initiate
or promote carcinogenesis and influence anticancer immunosurveillance [144,145]. Thus, changes in
microbiota composition are being evaluated as biomarkers for cancer diagnosis or prognosis [146,147].
The role of the gut microbiota in promoting or protecting against CRC has been studied. So far,
these investigations have mainly been addressed to the conventional pathway, rather than the serrated
one [148–151]. These analyzes particularly focused on the Gram-negative bacterium Fusobacterium
nucleatum (F. nucleatum), which is rarely present in the gut of healthy people [152].
The overabundance of F. nucleatum has been associated with CRC progression [153,154]. In this
way, F. nucleatum is involved in mucosal inflammation and promotes colorectal carcinogenesis by
modulating E-cadherin/beta-catenin signaling. Its detection has been related to particular CRC
subtypes [155]. Precisely, F. nucleatum has been linked with CIMP and MSI CRCs, thus encouraging its
exploitation as a prognostic biomarker [156].
Regarding the serrated pathway, it has been evidenced that F. nucleatum is present in 56% of
CRCs but appears less frequent in premalignant lesions. F. nucleatum was not associated with serrated
precursor polyps, but was related to CIMP-H status and to large tumors, comforting its role in CRC
progression [157]. The study also demonstrated an increasing density of F. nucleatum in SSA/Ps along
the path between the sigmoid and the cecum. This observation was explained by the anatomy of the
crypts in SSA/P. These crypts appeared rich with mucinous cells producing high mucus content which
favors the survival of the bacteria.
Another study by Park et al. investigated the composition of the gut microbiota, including
the presence of F. nucleatum, in patients with tubular adenoma and SSA/P [158]. The abundance of
Fusobacteria was comparable between the two subtypes of adenomas but lower in comparison to the
CRC group. A similar observation was reported by Ito et al. leading to the conclusion that Fusobacteria
could contribute to both conventional and serrated pathways [157,158].
The Human Microbioma Projects 1 and 2 (HMP1 and HMP2) directed by the National Institute
of Health (NIH, Bethesda, MD, USA) aim at collecting and comparing the human microbioma in
healthy and diseased conditions [159]. Available data already highlighted the great variability of the
microbioma across different physiopathological and environmental conditions. Future investigations
should benefit to precision medicine.
Thus, new studies will be necessary to correlate the gut microbiome profile with the serrated
adenoma-carcinoma pathway, and to identify novel biomarkers predictive of specific serrated lesions.
9. Clinical Relevance of Molecular Alterations in the Serrated Colorectal Pathway
Molecular heterogeneity among the subtypes of serrated colorectal tumors translates into a variety
of clinical and prognostic implications [19,160]. Precisely, clinicopathological features have been related
to the presence of BRAF mutations, MSI and CIMP in serrated CRCs. Interestingly, geographical
location seems contributing to such molecular heterogeneity. For instance, in contrast to Eastern
populations, Western populations show prevalent BRAF mutated, CIMP, MSI CRCs [41].
The clinical role of MSI and CIMP has not been precisely described as opposed to BRAF and KRAS
mutations. In general, BRAF mutated, MSI and CIMP CRCs are more frequent in females and often
localized in the proximal colon [98,161]. MSI CRCs present a good prognosis, while BRAF mutated and
CIMP tumors are related to a later age-of-onset and to a poor clinical outcome [38,65]. Serrated BRAF
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mutated tumors have also been associated with heavy smoking [162]. The latter shows a negative
prognostic outcome especially in the late stages of the disease, is associated with aggressive phenotypes,
and seems to favor metastases in the peritoneum rather than in the liver or lungs [163,164]. Metastatic
BRAF mutated CRCs do not respond to anti-EGFR treatment, with or without chemotherapy [165].
Moreover, the presence of mutations in BRAF has not demonstrated a predictive value for CRC therapy,
so far [161]. The 5-year disease-free survival rate and overall survival appear poor in BRAF mutated
patients even after lung/liver metastasectomy [161,163].
KRAS mutations are clinically heterogeneous as illustrated by their involvement in both traditional
and serrated CRC pathways. KRAS mutated tumors have been correlated with high body weight.
An association between KRAS mutated tumors and female gender has also been raised in the literature
but remains controversial [166,167]. KRAS mutated tumors have been mainly explored in metastatic
CRCs and associated with a poor outcome, notably a low 5-year disease-free survival, but are also
associated with a short cancer-specific survival in stage I CRCs [19,168].
CRCs harboring KRAS mutations also show resistance to anti-EGFR treatments and a negative
response to 5-fluorouracil-based therapies [169]. In addition, KRAS mutations combined with MSS can
increase the metastatic progression [170].
MSI is usually a molecular marker of a favorable prognosis independent of BRAF, KRAS, and
CIMP status [19]. MSI is also associated with a lower frequency of late-stage diseases [171,172]. Patients
with MSI cancers usually show a better prognosis and a longer disease-free survival with respect to MSS
tumors [173]; they also benefit from chemotherapy [174]. However, patients with metastatic MSI CRCs
having BRAF mutations show a poor survival rate [175]. The MSI test is recommended for patients
with stage II CRC in order to evaluate chemotherapy-based strategies [176]. In fact, 5-fluorouracil
treatment has no positive effect on survival in patients with MSI CRCs [177].
MSS cancer, developing from TSA or SSA/Ps, is related to a poor prognosis [172,178]. Several
studies reported that MSS CRCs, associated with BRAF mutations, show higher mortality and decreased
overall survival with respect to both MSI/BRAF mutated and MSS/KRAS mutated cancers [179–181].
The good prognosis of MSI/BRAF mutated cancers may be related to the increased immune response
in MSI tumor [182].
CIMP tumors are clinically heterogeneous. CIMP-L CRCs are associated with male gender, while
CIMP-Hs show a female preponderance and tend to manifest at a later age and are associated with
cigarette smoking [73]. The prognostic value of CIMP remains controversial especially for metastatic
CRCs, perhaps because of their high molecular heterogeneity. In fact, although CIMP is mostly reported
as a negative prognostic factor in CRC patients, several studies demonstrated that its prognostic value
can be influenced by BRAF/KRAS and MSI status [183–185]. Among them, CIMP-H, MSS, BRAF
mutated tumors show the worst prognosis of all CRCs [19,22,186]. The role of CIMP in tumor response
to therapy is also controversial [187]. Nevertheless, CIMP-H stage III CRC patients can benefit from
adjuvant irinotecan plus 5-fluorouracil chemotherapy [188].
Finally, epigenetic alterations can also influence clinical outcome of CRC patients. Hypermethylation
in MLH1 or MGMT predicts good prognosis, whereas hypermethylation in p16 or hypomethylation in
the promoters of LINE-1 and IGF-2 are related to poor prognosis [19,113,189–191].
In conclusion, growing knowledge of the genetic mutations characterizing the different colorectal
tumor subtypes, as well as their alterations at the epigenetic and signaling levels, is critical for
better classifying CRCs, and therefore, for personalizing the treatments to reach superior efficacy
(precision medicine).
10. Conclusions
This review is an excursus on the serrated pathway in colorectal carcinogenesis. It reports the new
major genetic and epigenetic alterations, as well as the relevant emerging role of the gut microbiota,
in serrated CRC. The molecular characterization of serrated polyps provides necessary information for
their correct classification. Such classification allows to match the clinical signs and symptoms with
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the natural history of the disease; a critical consideration for adapting the care of the patient following
diagnosis and during treatment follow-up.
Thus, we highlighted the need for combining a more precise set of molecular analyses together
with histological assessments to better differentiate the serrated colorectal polyps.
In contrast to the conventional pathway, characterized by KRAS mutations, CIN, CIMP negative,
and MSS, the progression from serrated polyp toward cancer seems driven and featured by alternative
molecular imprints, with different prognostic significance.
Generally, there are two major serrated pathways, namely sessile and traditional, which differ in
the lesions encountered along the oncogenic process: SSA/P and TSA, respectively. On the one hand,
SSA/Ps are characterized by BRAF mutations, CIMP-H and MLH1 promoter methylation. On the other
hand, TSA lesions harbor KRAS or BRAF mutations and can be MSS, CIMP-H or CIMP-L.
To shed light on the malignant adenoma-to-carcinoma progression, several transcriptomic
and epigenomic studies have demonstrated that serrated polyps display a different molecular
expression profile compared to the CC, thus identifying, for each serrated lesion, panels of
markers for subtype-specific molecular signature, including microRNAs and lncRNAs. Nevertheless,
the classification of serrated CRCs, and their respective diagnostic and prognostic values, still remain to
be clarified. As underlined above, such clarification is rendered difficult by the high heterogeneity and
the undiscovered molecular features of serrated lesions. Thus, the definition of new specific genetic
and epigenetic features will be useful for supporting clinical-decision making and driving the choice of
the most appropriate therapeutic approach.
Further studies will be necessary to confirm the emerging role of the gut microbiota, to establish
a commonly accepted molecular classification of serrated lesions and to identify novel targets for
treating CRC. The availability of advanced technologies able to investigate the molecular bases of
human diseases with high resolution will further improve this field. Among them, omic analyses at a
single cell level (genomics, transcriptomics, proteomics, metabolomics, etc.), applicable to dissociated
tumors or circulating tumor cells, will likely contribute to identify new biomarkers. All these advances
will facilitate personalized endoscopic, histologic and molecular surveillance of serrated CRC lesions
and ultimately improve their clinical management.
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